Clinical Trials Directory

Trials / Completed

CompletedNCT00002232

A Study of GENEVAX-HIV, a Possible Vaccine

GENEVAX-HIV (APL 400-003), a Candidate DNA Vaccine: A Pilot Study of GENEVAX-HIV Given by Intramuscular or Intradermal Administration in HIV Seronegative Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
—
Sponsor
Wyeth-Lederle Vaccines · Industry
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to see if it is safe to give GENEVAX-HIV, a potential HIV vaccine, to HIV-negative volunteers. The study also compares the effects of GENEVAX-HIV injected into the muscle to the effects of the drug when injected into the skin.

Detailed description

Volunteers receive either intradermal or intramuscular injections of GENEVAX-HIV; humoral and cellular responses are assessed accordingly.

Conditions

Interventions

TypeNameDescription
BIOLOGICALAPL 400-003

Timeline

First posted
2001-08-31
Last updated
2005-06-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00002232. Inclusion in this directory is not an endorsement.